InMed Pharmaceuticals (INM) Soars on Alzheimer’s Breakthrough: INM‑901 Study Sparks 20%+ Stock Rally on November 20, 2025
InMed Pharmaceuticals shares surged over 20% in after-hours and pre-market trading following new preclinical data for its Alzheimer’s candidate INM-901. The company reported successful large-animal studies showing robust bioavailability and no adverse neurological effects. INM traded in the $1.49–$1.55 range Thursday morning on heavy volume, with market cap estimates between $3–5 million.
